Net worth
$26B
Forbes Real-Time · as of Sep 24, 2026
Latest moves
No moves from Dilip Shanghvi in the digest yet. The archive grows every morning.
Recent SEC filings
This person doesn't file with the SEC.
Footprint
Companies
Sun Pharmaceutical IndustriesSUNPHARMA / 524715 · NSE / BSE · Founder, controlling shareholder · promoter group 54.48% · as of Jun 2026
source ↗More
- Ticker
- SUNPHARMA / 524715
- Exchange
- NSE / BSE
- Role
- Founder, controlling shareholder (Managing Director per Wikipedia)
- Stake
- promoter group 54.48%
- Stake as of
- 2026-06
Organon & Co. (being acquired by Sun Pharma)OGN · NYSE · Target of Sun Pharma's ~$11.75B… · $13.72 ▼ 0.07%
source ↗More
- Ticker
- OGN
- Exchange
- NYSE
- Role
- Target of Sun Pharma's ~$11.75B acquisition announced April 2026
Taro Pharmaceutical IndustriesFully owned by Sun Pharma after Jan… · 100% · as of Jan 2024
source ↗More
- Role
- Fully owned by Sun Pharma after Jan 2024 buyout of minority (~$347.7M)
- Stake
- 100%
- Stake as of
- 2024-01
Private deals
Sun Pharma agreed to buy Organon & Co. for ~$11.75B, described as India's biggest pharma dealApr 2026
source ↗Sun Pharma acquired Checkpoint Therapeutics for up to ~$355MMay 2025
source ↗Moody's (Baa1) and S&P (BBB+) assigned ratings to Sun Pharma reflecting the Organon deal; GIFT City treasury…Sep 2026
source ↗More
- In full
- Moody's (Baa1) and S&P (BBB+) assigned ratings to Sun Pharma reflecting the Organon deal; GIFT City treasury subsidiary incorporated (both 2026-09-08, per exchange filings summarized by Screener)
- Date
- 2026-09-08
Research gaps: USFDA warning letters and import alerts on Sun plants, the SEBI matters, and US generic price-fixing litigation are not verified (search budget exhausted). Organon per-share price and expected close date not confirmed. No real estate or foundation verified.
Prices via Finnhub · as of Sep 24, 2026 4:00 PM ET. For information only.